First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers

被引：0

作者：

Thierry Landre

Gaetan Des Guetz

Kader Chouahnia

Cherifa Taleb

Alain Vergnenègre

Christos Chouaïd

机构：

[1] Hôpital René-Muret,UCOG 93

[2] APHP,Service d’Oncologie Médicale

[3] Centre Hospitalier Delafontaine,Service d’Oncologie Médicale

[4] Hôpital Avicenne,Service d’Oncogériatrie

[5] APHP,Service de Pneumologie

[6] Hôpital René-Muret,undefined

[7] APHP,undefined

[8] Service d’Oncologie Médicale,undefined

[9] Unité d’Oncologie Thoracique,undefined

[10] Centre Hospitalier Intercommunal (CHI) Créteil,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷

关键词：

Non-small-cell lung cancer; PD-L1; Anti-PD-1/PD-L1; Immunotherapy; Meta-analysis; Management; Chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：441 / 448

页数：7

共 50 条

[41] PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
Mei Ji
Yan Liu
Qing Li
Xiao-Dong Li
Wei-Qing Zhao
Hanze Zhang
Xiaofei Zhang
Jing-Ting Jiang
Chang-Ping Wu
Journal of Translational Medicine, 13
[42] PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma
Song, Mengjia
Huang, Yue
Hong, Ye
Liu, Juan
Zhu, Jia
Lu, Suying
Wang, Juan
Sun, Feifei
Huang, Junting
Xu, Jiaqian
Tang, Yan
Xia, Jian-Chuan
Zhang, Yizhuo
ONCOIMMUNOLOGY, 2024, 13 (01):
[43] Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer A Review
Sacher, Adrian G.
Gandhi, Leena
JAMA ONCOLOGY, 2016, 2 (09) : 1217 - 1222
[44] PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
Ji, Mei
Liu, Yan
Li, Qing
Li, Xiao-Dong
Zhao, Wei-Qing
Zhang, Hanze
Zhang, Xiaofei
Jiang, Jing-Ting
Wu, Chang-Ping
JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
[45] Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations
Ferrara, Roberto
Lo Russo, Giuseppe
Ciniselli, Chiara Maura
Piva, Annamaria
Bassani, Barbara
Jachetti, Elena
Calareso, Giuseppina
Duroni, Valeria
Di Gregorio, Settimio
Proto, Claudia
Prelaj, Arsela
De Toma, Alessandro
Occhipinti, Mario
Brambilla, Marta
Manglaviti, Sara
Mazzeo, Laura
Rinaldi, Arturo
Beninato, Teresa
Ganzinelli, Monica
De Braud, Filippo
Garassino, Marina Chiara
Verderio, Paolo
Colombo, Mario Paolo
Sangaletti, Sabina
CANCER RESEARCH, 2023, 83 (07)
[46] PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data
Ge, Yihui
Zhan, Yujing
He, Jie
Li, Juan
Wang, Jian
Wei, Xiaojuan
Wang, Chunni
Gao, Aiqin
Sun, Yuping
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (03)
[47] PD-L1 AND PD-1 EXPRESSION IN MOLECULARLY SELECTED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS
D'Incecco, A.
Andreozzi, M.
Ludovini, V.
Rossi, E.
Landi, L.
Minuti, G.
Fontanini, G.
Crino, L.
Terracciano, L.
Cappuzzo, F.
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S18 - S19
[48] Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
Kim, C. G.
Kim, K. H.
Pyo, K-H
Xin, C-F
Hong, M. H.
Ahn, B-C
Kim, Y.
Choi, S. J.
Yoon, H., I
Lee, J. G.
Lee, C. Y.
Park, S. Y.
Park, S-H
Cho, B. C.
Shim, H. S.
Shin, E-C
Kim, H. R.
ANNALS OF ONCOLOGY, 2019, 30 (07) : 1104 - 1113
[49] PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data
Yihui Ge
Yujing Zhan
Jie He
Juan Li
Jian Wang
Xiaojuan Wei
Chunni Wang
Aiqin Gao
Yuping Sun
Journal of Cancer Research and Clinical Oncology, 150
[50] PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas
Tian, Zhichao
Yao, Weitao
FRONTIERS IN IMMUNOLOGY, 2022, 13

← 1 2 3 4 5 →